Skip to Main Content

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

Conditions

Diseases of the Cardiovascular System

Phase III

What is the purpose of this trial?

Objectives

  • Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
  • Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
  • Trial with
    University of Cincinnati
  • Start Date
    11/26/2018
  • End Date
    01/17/2022
Trial Image

For more information about this study, contact:

Sara Jasak

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/25/2020
  • Study HIC
    #2000024124